Charles J. Glueck - Publications, H-index & Citations

Back

Charles J. Glueck

washington university (wustl)

82H-index

710Paper Count

2.6WCitation Count

Published Papers 98

Publication Date

Turner's Syndrome, Glucagon-like Peptide 1, and Glucose-dependent Insulinotropic Polypeptide Agents: Silver Bullets?

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2024-06-25

OAAI

Glueck, Charles J.

Save

Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics

METABOLISM-CLINICAL AND EXPERIMENTAL

IF11.9

2019-03-01

263

PREAI

Glueck, Charles J.; Goldenberg, Naila

Save

Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events

JOURNAL OF CLINICAL MEDICINE

IF2.9

2018-12-21

OAAI

Glueck, Charles J.; Goldenberg, Naila; Wang, Ping

Save

Alirocumab in high-risk patients: Observations from the open-label expanded use program

JOURNAL OF CLINICAL LIPIDOLOGY

IF4.6

2018-05-01

OAAI

Glueck, Charles J.; Brown, Alan; Goldberg, Anne C.; McKenney, James M.; Kantaros, Louis; Stewart, John; Elassal, Joseph; Koren, Andrew

Save

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

LIPIDS IN HEALTH AND DISEASE

IF4.2

2017-07-24

OAAI

Choi, Joshua; Khan, Amir M.; Jarmin, Michael; Goldenberg, Naila; Glueck, Charles J.; Wang, Ping

Save

Efficacy Of Alirocumab And Evolocumab In Lowering Low-density Lipoprotein Cholesterol To Less Than 70 mg/dL In 107 High-risk Hypercholesterolemic Patients

JACC-CARDIOVASCULAR INTERVENTIONS

IF11.4

2017-02-01

OAAI

Min, Sarah; Goldenberg, Naila; Glueck, Charles; Wang, Ping

Save

Head to Head Efficacy of Alirocumab 75 and 150 mg vs Evolocumab 140 mg in Real World Patients

JACC-CARDIOVASCULAR INTERVENTIONS

IF11.4

2017-02-01

OAAI

Min, Sarah; Goldenberg, Naila; Glueck, Charles; Wang, Ping

Save

Eligibility for PCSK9 Inhibitor Treatment in 1090 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center with LDL Cholesterol >=70 mg/dl Despite Maximal Tolerated Cholesterol Lowering Therapy

JACC-CARDIOVASCULAR INTERVENTIONS

IF11.4

2017-02-01

OAAI

Lee, Kevin; Min, Sarah; Prince, Marloe; Glueck, Charles; Wang, Ping; Lee, Kenneth

Save

Atherothrombosis in 153 Patients with Premature Coronary Artery Disease <= Age 45

JACC-CARDIOVASCULAR INTERVENTIONS

IF11.4

2017-02-01

OAAI

Lee, Kevin; Min, Sarah; Prince, Marloe; Glueck, Charles; Wang, Ping; Lee, Kenneth

Save

Treatment Of Severe Hypertriglyceridemia (500-≥ 2000 Mg/dl) In 405 Patients

JACC-CARDIOVASCULAR INTERVENTIONS

IF11.4

2017-02-01

PREAI

Prince, Marloe; Jarmin, Michael; Lee, Kevin; Makadia, Frini; Milgrom, Alexander; Rothschild, Matan; Min, Sarah; Schlamm, Ilana; Mahida, Chris; Duhon, Greg; Wang, Ping; Glueck, Charles J.

Save

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

LIPIDS IN HEALTH AND DISEASE

IF4.2

2017-01-23

OAAI

Shah, Parth; Glueck, Charles J.; Goldenberg, Naila; Min, Sarah; Mahida, Chris; Schlam, Ilana; Rothschild, Matan; Huda, Ali; Wang, Ping

Save

Low serum vitamin D, statin associated muscle symptoms, vitamin D supplementation

ATHEROSCLEROSIS

IF5.7

2017-01-01

PREAI

Glueck, Charles J.; Lee, Kevin; Prince, Marloe; Milgrom, Alexander; Makadia, Frini; Wang, Ping

Save

Pathognomonic Palmar Crease Xanthomas of Apolipoprotein E2 Homozygosity-Familial Dysbetalipoproteinemia

JAMA DERMATOLOGY

IF11

2016-11-01

PREAI

Rothschild, Matan; Duhon, Greg; Riaz, Rashid; Jetty, Vybhav; Goldenberg, Naila; Glueck, Charles J.; Wang, Ping

Save

Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

LIPIDS IN HEALTH AND DISEASE

IF4.2

2016-08-18

OAAI

Shah, Parth; Glueck, Charles J.; Jetty, Vybhav; Goldenberg, Naila; Rothschild, Matan; Riaz, Rashid; Duhon, Gregory; Wang, Ping

Save

Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy

LIPIDS IN HEALTH AND DISEASE

IF4.2

2016-03-12

OAAI

Glueck, Charles J.; Shah, Parth; Goldenberg, Naila; Prince, Marloe; Lee, Kevin; Jetty, Vybhav; Kumar, Ashwin; Goldenberg, Michael; Wang, Ping

Save

Age of Menarche and Oligomenorrhea in Adolescence: Cardiometabolic Ramifications in Adulthood

JOURNAL OF PEDIATRICS

IF3.5

2015-08-01

PREAI

Glueck, Charles J.; Wang, Ping

Save

Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy

MAYO CLINIC PROCEEDINGS

IF6.7

2015-08-01

PREAI

Baillargeon, Jacques; Urban, Randall J.; Morgentaler, Abraham; Glueck, Charles J.; Baillargeon, Gwen; Sharma, Gulshan; Kuo, Yong-Fang

Save

Testosterone, thrombophilia, thrombosis

TRANSLATIONAL RESEARCH

IF5.9

2015-05-01

PREAI

Freedman, Joel; Glueck, Charles J.; Prince, Marloe; Riaz, Rashid; Wang, Ping

Save

Adolescent Oligomenorrhea (Age 14-19) Tracks Into the Third Decade of Life (Age 20-28) and Predicts Increased Cardiovascular Risk Factors and Metabolic Syndrome

METABOLISM-CLINICAL AND EXPERIMENTAL

IF11.9

2015-04-01

PREAI

Glueck, Charles J.; Woo, Jessica G.; Khoury, Philip R.; Morrison, John A.; Daniels, Stephen R.; Wang, Ping

Save

Adolescent and Young Adult Female Determinants of Visceral Adipose Tissue at Ages 26-28 Years

JOURNAL OF PEDIATRICS

IF3.5

2015-04-01

PREAI

Glueck, Charles J.; Wang, Ping; Woo, Jessica G.; Morrison, John A.; Khoury, Philip R.; Daniels, Stephen R.

Save

Research Directions